Holen Sie sich die Stockscreener-App
1.425
1.41%
0.005
Schlusskurs vom Vortag:
$1.42
Offen:
$1.44
24-Stunden-Volumen:
484.62K
Relative Volume:
0.42
Marktkapitalisierung:
$88.73M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-73.79M
KGV:
-0.7745
EPS:
-1.84
Netto-Cashflow:
$-77.44M
1W Leistung:
+25.22%
1M Leistung:
-65.55%
6M Leistung:
+27.43%
1J Leistung:
-10.56%
1-Tages-Spanne:
$1.35
$1.44
1-Wochen-Bereich:
$1.13
$1.52
52-Wochen-Spanne:
$0.8332
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
Firmenname
Pyxis Oncology Inc
Sektor
Branche
Telefon
(617) 221-9059
Adresse
321 HARRISON AVENUE, BOSTON
Vergleichen Sie PYXS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.425 | 88.42M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.75 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
807.70 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
395.33 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
796.67 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
169.28 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-03 | Fortgesetzt | Stifel | Buy |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2024-11-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-08-08 | Eingeleitet | Stifel | Buy |
| 2024-05-07 | Fortgesetzt | Jefferies | Buy |
| 2024-02-09 | Eingeleitet | BTIG Research | Buy |
| 2024-01-23 | Eingeleitet | Leerink Partners | Outperform |
| 2023-09-05 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-11-02 | Eingeleitet | BofA Securities | Neutral |
| 2021-11-02 | Eingeleitet | Credit Suisse | Outperform |
| 2021-11-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Pyxis Oncology Inc Aktie (PYXS) Neueste Nachrichten
After-Hours Gainers: ALXO, GMED, ACRV, And Biotech Peers Rally On Trial Data And Earnings Updates - RTTNews
Is Pyxis Oncology Inc. stock recession proofHead and Shoulders Patterns & Create Your Free Watchlist Instantly - ulpravda.ru
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Goosehead Insurance Inc 2OX Stock Analysis and ForecastMomentum Trading Signals & Exceptional Return Capital - earlytimes.in
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Pyxis Oncology Inc. stock positioned well for digital economyShort-Term Trading Alerts & Easy Tools to Analyze Your Investment Risk - bollywoodhelpline.com
Pyxis Oncology Inc. (PYXS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Short Interest in Pyxis Oncology, Inc. (NASDAQ:PYXS) Drops By 57.3% - MarketBeat
Pyxis Oncology Stock Plunge: A Buy Signal? - StocksToTrade
Pyxis Oncology Stock Slides 73% With A 7-Day Losing Spree - Trefis
Will Pyxis Oncology Inc. stock benefit from automationEarnings Recap Summary & Weekly Setup with ROI Potential - Улправда
Bear Alert: Is Pyxis Oncology Inc. stock a contrarian buy2025 Year in Review & Safe Entry Momentum Stock Tips - Улправда
How Pyxis Oncology Inc. stock compares to growth peersQuarterly Profit Summary & Weekly High Conviction Trade Ideas - Улправда
Pyxis Oncology (NASDAQ:PYXS) Lowered to Sell Rating by Wall Street Zen - Defense World
Pyxis Oncology Stock 6-Day Losing Spree: Stock Falls 71% - Trefis
HC Wainwright & Co. Maintains Pyxis Oncology (PYXS) Buy Recommendation - Nasdaq
RBC Capital Maintains Pyxis Oncology (PYXS) Outperform Recommendation - Nasdaq
Pyxis Oncology sees cash runway into 4Q26 - MSN
Is Pyxis Oncology Inc. stock a dividend growth opportunity2025 Bull vs Bear & Long-Term Safe Return Strategies - DonanımHaber
Pyxis Oncology stock price target raised to $7 by H.C. Wainwright - Investing.com Nigeria
RBC Capital Lowers Price Target for Pyxis Oncology (PYXS) to $5, Maintains Outperform Rating | PYXS Stock News - GuruFocus
Analysts Sound Alarm On Pyxis Oncology's Tiny Trial - Benzinga
RBC Cuts Price Target on Pyxis Oncology to $5 From $8, Keeps Outperform, Speculative Risk - marketscreener.com
Pyxis plummets following phase 1 data on candidate for head and neck cancer - MSN
Is Pyxis Oncology Inc. stock a contrarian buy2025 Trade Ideas & Risk Adjusted Buy/Sell Alerts - Улправда
Pyxis Oncology Sees Unusually High Options Volume (NASDAQ:PYXS) - Defense World
Pyxis Oncology reports positive data for head and neck cancer drug By Investing.com - Investing.com South Africa
Fed Meeting: Is Pyxis Oncology Inc. stock positioned well for digital economyMarket Trend Report & AI Enhanced Trade Execution Alerts - Улправда
Pyxis Oncology stock falls as RBC cuts price target on complex trial data - Investing.com Australia
Pyxis Oncology stock falls as RBC cuts price target on complex trial data By Investing.com - Investing.com South Africa
Pyxis Oncology reports positive data for head and neck cancer drug - Investing.com Nigeria
Pyxis Oncology Stock (PYXS) Opinions on Phase 1 Cancer Drug Data - Quiver Quantitative
Stock Traders Buy Large Volume of Pyxis Oncology Put Options (NASDAQ:PYXS) - MarketBeat
Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell CarcinomaSlideshow (NASDAQ:PYXS) 2025-12-18 - Seeking Alpha
Transcript : Pyxis Oncology, Inc.Special Call - marketscreener.com
Pyxis Oncology stock plummets after early-stage cancer drug data By Investing.com - Investing.com South Africa
Pyxis Oncology stock plummets after early-stage cancer drug data - Investing.com
Pyxis Oncology’s Stock Moves: Time for Investors to Act? - timothysykes.com
PYXS: MICVO shows strong efficacy and safety in R/M HNSCC, both as monotherapy and with KEYTRUDA - TradingView — Track All Markets
Pyxis Oncology Reports Strong MICVO Data and Financing - TipRanks
Pyxis Oncology, Inc. Announces Positive Preliminary Phase 1 Data for MICVO - TradingView — Track All Markets
PYXS FinancialsIncome Statement - Quiver Quantitative
Pyxis Oncology (PYXS) shows promising MICVO results and extends cash runway - Stock Titan
Finanzdaten der Pyxis Oncology Inc-Aktie (PYXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):